Related Experiment Video

Updated: May 15, 2026

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice
11:10

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice

Published on: November 16, 2011

Extraglycemic effects of glp-1-based therapeutics: addressing metabolic and cardiovascular risks associated with type

Susan Herzlinger1, Edward S Horton

  • 1Joslin Diabetes Center, Harvard Medical School, Boston, MA 02215, United States.

Diabetes Research and Clinical Practice
|January 22, 2013
PubMed
Abstract

Insights

Glucagon-like peptide (GLP)-1 receptor agonists show promise for treating cardiovascular issues in type 2 diabetes patients. Further research is needed to confirm these beneficial effects for patient care.

Area of Science:

  • Endocrinology
  • Cardiology
  • Metabolic Diseases

Background:

  • Glucagon-like peptide (GLP)-1 receptor agonists (RAs) exhibit diverse effects on obesity, hypertension, and cardiovascular disease.
  • GLP-1 RAs influence food intake and gastric emptying, contributing to weight reduction.
  • Preclinical studies show native GLP-1 and GLP-1 RAs possess cardioprotective properties.

Purpose of the Study:

  • To investigate if widespread GLP-1 receptor expression supports GLP-1-based therapeutics' effects on cardiac function, blood pressure, food intake, and gastric emptying.
  • To explore the potential of GLP-1 RAs in managing cardiovascular comorbidities in type 2 diabetes.

Main Methods:

  • A literature search was conducted using PubMed for studies on GLP-1 and GLP-1 RAs.
  • Review of recent scientific literature on GLP-1 receptor agonists and their therapeutic effects.

Main Results:

  • Preliminary data suggest native GLP-1 improves endothelial function and reduces vascular inflammation.
  • GLP-1 RAs demonstrate renoprotective, antihypertensive, and lipid-lowering effects.
  • Liraglutide, a GLP-1 RA, positively impacts markers of endothelial dysfunction, including TNF-α and PAI-1.

Conclusions:

  • GLP-1 RAs may offer benefits for type 2 diabetes patients with cardiovascular risks.
  • Further investigation is required to validate extraglycemic and extrapancreatic effects.
  • Translating these findings into improved patient care necessitates additional clinical studies.

More Related Videos

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory10:03

A Zebrafish Model of Diabetes Mellitus and Metabolic Memory

Published on: February 28, 2013

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Type II Diabetes II: Pathophysiology01:24

Type II Diabetes II: Pathophysiology

PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.